FIELD: genetic engineering; molecular biology; medicine.
SUBSTANCE: group of inventions relates to the field of genetic engineering, molecular biology and medicine, in particular to methods for the treatment of amyloidosis of a light chain, using chimeric antigen receptors (hereinafter – CAR) targeted to CS1. The method for the treatment of amyloidosis of a light chain includes the administration to a patient of a population of human T-cells transduced by a vector containing an expression cassette encoding CAR, or T-cells expressing CAR. The chimeric antigen receptor contains an amino acid sequence selected from SEQ ID NO: 30, 31, 33, 34, 36, 37, 39, 40, 42, 43, 44 and 45.
EFFECT: inventions allow for an increase in the efficiency of therapy of amyloidosis of a light chain by CAR T-cells.
10 cl, 9 dwg, 5 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| T-CELLS MODIFIED WITH A CHIMERIC ANTIGEN RECEPTOR TARGETING CS1 | 2015 |
|
RU2727451C2 |
| CHIMERIC ANTIGEN RECEPTORS TARGETING HER2 | 2016 |
|
RU2753695C2 |
| IMMUNOTHERAPY CELLS DESIGNED FOR TARGETING ANTIGEN PRESENT SIMULTANEOUSLY ON IMMUNE CELLS AND ON PATHOLOGICAL CELLS | 2015 |
|
RU2714258C2 |
| CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
| CHIMERIC ANTIGEN RECEPTORS AIMED AT PSCA | 2016 |
|
RU2759879C2 |
| CHIMERIC ANTIGENE RECEPTORS TARGETTING FLT3 | 2018 |
|
RU2820859C2 |
| MUC16-SPECIFIC CHIMERIC ANTIGEN RECEPTORS AND THEIR USE | 2019 |
|
RU2795198C2 |
| CHIMERIC ANTIGEN RECEPTOR T-CELLS (CAR-T) FOR CANCER TREATMENT | 2019 |
|
RU2811466C2 |
| CELL | 2014 |
|
RU2717984C2 |
| CELL | 2014 |
|
RU2732236C2 |
